Clinical Researches of New Drugs for Non-alcoholic Fatty Liver Disease
10.13748/j.cnki.issn1007-7693.20224239
- VernacularTitle:非酒精性脂肪性肝病新药的临床研究进展
- Author:
Changlin TIAN
1
;
Yuqin LI
1
;
Hongtao LIU
2
Author Information
1. The Postgraduate College of Hebei Medical University, Shijiazhuang 050000, China；Clinical Research Center of Hebei General Hospital, Shijiazhuang 050000, China
2. Clinical Research Center of Hebei General Hospital, Shijiazhuang 050000, China
- Publication Type:Journal Article
- Keywords:
non-alcoholic fatty liver disease ；metabolic-related fatty liver disease；combined drugs
- From:
Chinese Journal of Modern Applied Pharmacy
2024;41(6):858-863
- CountryChina
- Language:Chinese
-
Abstract:
Non-alcoholic fatty liver disease(NAFLD) is the most common clinical chronic liver disease with a global incidence of about 25%, which could progress to liver fibrosis, liver cirrhosis, and hepatocellular carcinoma, and posing a serious threat to human health. At present, China has not approved any therapeutic drugs for marketing, and the research and development of new drugs is imminent. It is difficult to achieve great efficacy with a single medication due to the complex mechanism of NAFLD. The combination of several drugs with different pharmacological mechanisms is an inevitable trend for the future treatment of NAFLD, which is expected to reduce the adverse effects of the drug and play a synergistic effect to produce better efficacy. This paper reviews the latest clinical research progress of NAFLD combined drugs, so as to provide a reference for the subsequent new drug development and clinical rational drugs application of NAFLD.
